1. INTRODUCTION
2. EXECUTIVE SUMMARY
3. PREMIUM INSIGHTS
4. MARKET OVERVIEW
*Outlines emerging trends, technology impact, and regulatory signals affecting growth trajectory and stakeholder decisions.*
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.2.4 CHALLENGES
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5. INDUSTRY TRENDS
*Covers the key developments, trend analysis, and actionable insights to support strategic planning and positioning.*
5.1 PORTER’S FIVE FORCES ANALYSIS
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 GLOBAL PHARMACEUTICAL R&D EXPENDITURE AND PRODUCTIVITY TRENDS
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY PLATFORMS, BY KEY PLAYERS (2025)
5.5.2 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY SOFTWARE AND SERVICES, BY REGION (2025)
5.6 KEY CONFERENCES AND EVENTS, 2026-2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 CASE STUDY ANALYSIS
5.10 IMPACT OF US TARIFFS AND TRADE POLICY (2025-2026) ON THE AI IN DRUG DISCOVERY MARKET
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.10.4 IMPACT ON COUNTRIES/REGIONS
5.10.4.1 US
5.10.4.2 EUROPE
5.10.4.3 ASIA PACIFIC
5.10.5 IMPACT ON END-USE INDUSTRIES
6. TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.2 COMPLEMENTARY TECHNOLOGIES
6.3 ADJACENT TECHNOLOGIES
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.6 FUTURE APPLICATIONS
7. REGULATORY LANDSCAPE
7.1 INTRODUCTION
7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.3 REGIONAL FRAMEWORK
7.3.1 NORTH AMERICA
7.3.2 EUROPE
7.3.3 ASIA PACIFIC
7.3.4 LATIN AMERICA
7.3.5 MIDDLE EAST & AFRICA
7.4 INDUSTRY STANDARDS
8. CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9. AI IN DRUG DISCOVERY MARKET, BY PROCESS (MARKET SIZE & FORECAST TO 2031)
9.1 INTRODUCTION
9.2 TARGET IDENTIFICATION & SELECTION
9.3 TARGET VALIDATION
9.4 HIT IDENTIFICATION & PRIORITIZATION
9.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
9.6 LEAD OPTIMIZATION
9.7 CANDIDATE SELECTION AND VALIDATION
10. AI IN DRUG DISCOVERY MARKET, BY USE CASE (MARKET SIZE & FORECAST TO 2031)
10.1 INTRODUCTION
10.2 UNDERSTANDING DISEASE BIOLOGY
10.2.1 EVIDENCE SYNTHESIS AND SCIENTIFIC LITERATURE INTELLIGENCE
10.2.2 MULTI-OMICS INTEGRATION AND TARGET-DISEASE ASSOCIATION
10.2.3 EXPERIMENT DESIGN AND REAGENT/MODEL SELECTION
10.3 PROTEIN STRUCTURE AND INTERACTION PREDICTION
10.4 DRUG REPURPOSING (INCLUDING DRUG PRIORITIZATION)
10.5 DE NOVO DRUG DESIGN
10.5.1 SMALL MOLECULE DESIGN
10.5.2 VACCINE DESIGN
10.5.3 ANTIBODY & OTHER BIOLOGICS DESIGN
10.5.4 PROTEIN & ENZYME DESIGN
10.6 DRUG OPTIMIZATION
10.6.1 SMALL MOLECULE OPTIMIZATION
10.6.2 VACCINE OPTIMIZATION
10.6.3 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION
10.7 SAFETY AND TOXICITY PREDICTION
11. AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA (MARKET SIZE & FORECAST TO 2031)
11.1 INTRODUCTION
11.2 ONCOLOGY
11.3 INFECTIOUS DISEASES
11.4 NEUROLOGY
11.5 METABOLIC DISEASES
11.6 CARDIOVASCULAR DISEASES
11.7 IMMUNOLOGY
11.8 RARE & GENETIC DISORDERS
11.9 MENTAL HEALTH
11.10 OTHERS
12. AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE (MARKET SIZE & FORECAST TO 2031)
12.1 INTRODUCTION
12.2 END-TO-END SOLUTION PROVIDERS
12.3 NICHE/POINT SOLUTION PROVIDERS
12.4 AI TECHNOLOGY PROVIDERS
12.5 COMPUTE AND INFRASTRUCTURE PROVIDERS
12.6 BUSINESS PROCESS SERVICE PROVIDERS
13. AI IN DRUG DISCOVERY MARKET, BY AI TOOL (MARKET SIZE & FORECAST TO 2031)
13.1 INTRODUCTION
13.2 MACHINE LEARNING
13.2.1 DEEP LEARNING
13.2.1.1 TRANSFORMER-BASED ARCHITECTURES
13.2.1.2 GRAPH NEURAL NETWORKS (GNN)
13.2.1.3 CONVOLUTIONAL NEURAL NETWORKS (CNN)
13.2.1.4 DIFFUSION AND FLOW-BASED MODELS
13.2.1.5 GENERATIVE ADVERSARIAL NETWORKS (GAN) AND VARIATIONAL AUTOENCODERS (VAE)
13.2.1.6 RECURRENT AND SEQUENCE MODELS (RNN, LSTM)
13.2.1.7 OTHERS
13.2.2 SUPERVISED LEARNING
13.2.3 SELF-SUPERVISED AND REPRESENTATION LEARNING
13.2.4 REINFORCEMENT LEARNING
13.2.5 UNSUPERVISED LEARNING
13.2.6 OTHER MACHINE LEARNING TECHNOLOGIES
13.3 GENERATIVE AI
13.3.1 MOLECULAR GENERATIVE MODELS
13.3.2 PROTEIN AND BIOLOGICS GENERATIVE MODELS
13.3.3 LARGE LANGUAGE MODELS (LLMS)
13.4 FOUNDATION MODELS
13.4.1 CHEMISTRY FOUNDATION MODELS
13.4.2 PROTEIN LANGUAGE MODELS
13.4.3 BIOLOGY AND MULTI-OMICS FOUNDATION MODELS
13.5 AGENTIC AI AND AI CO-SCIENTISTS
13.5.1 AUTONOMOUS RESEARCH AGENTS AND WORKFLOW ORCHESTRATION
13.5.2 MULTI-AGENT REASONING SYSTEMS
13.5.3 LAB-IN-THE-LOOP AND CLOSED-LOOP EXPERIMENTATION
13.6 KNOWLEDGE GRAPHS AND SEMANTIC REASONING
13.7 NATURAL LANGUAGE PROCESSING (NLP)
13.8 COMPUTER VISION AND IMAGE ANALYSIS
13.9 PHYSICS-BASED AND HYBRID AI METHODS
14. AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT (MARKET SIZE & FORECAST TO 2031)
14.1 INTRODUCTION
14.2 ON-PREMISE SOLUTIONS
14.3 CLOUD-BASED SOLUTIONS
14.3.1 PUBLIC CLOUD
14.3.2 PRIVATE CLOUD
14.4 HYBRID SOLUTIONS
15. AI IN DRUG DISCOVERY MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031)
15.1 INTRODUCTION
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
15.2.1 LARGE PHARMACEUTICAL COMPANIES
15.2.2 SMALL & MID-SIZED BIOTECHNOLOGY COMPANIES
15.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CDMOS
15.4 RESEARCH CENTERS, ACADEMIC INSTITUTES, & GOVERNMENT ORGANIZATIONS
16. AI IN DRUG DISCOVERY MARKET, BY REGION (MARKET SIZE & FORECAST TO 2031)
16.1 INTRODUCTION
16.2 NORTH AMERICA
16.2.1 US
16.2.2 CANADA
16.3 EUROPE
16.3.1 GERMANY
16.3.2 UK
16.3.3 SWITZERLAND
16.3.4 FRANCE
16.3.5 ITALY
16.3.6 SPAIN
16.3.7 REST OF EUROPE
16.4 ASIA PACIFIC
16.4.1 CHINA
16.4.2 JAPAN
16.4.3 INDIA
16.4.4 SOUTH KOREA
16.4.5 AUSTRALIA
16.4.6 REST OF ASIA PACIFIC
16.5 LATIN AMERICA
16.5.1 BRAZIL
16.5.2 MEXICO
16.5.3 REST OF LATIN AMERICA
16.6 MIDDLE EAST & AFRICA
16.6.1 GCC COUNTRIES
16.6.1.1 SAUDI ARABIA
16.6.1.2 UAE
16.6.1.3 REST OF GCC
16.6.2 SOUTH AFRICA
16.6.3 REST OF MIDDLE EAST & AFRICA
17. COMPETITIVE LANDSCAPE
*STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL*
17.1 OVERVIEW
17.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
17.3 REVENUE AND FUNDING ANALYSIS OF KEY PLAYERS (2021-2025)
17.4 MARKET SHARE ANALYSIS (2025)
17.5 PLATFORM/SOFTWARE COMPARATIVE ANALYSIS
17.6 COMPANY EVALUATION MATRIX: KEY PLAYERS
17.6.1 STARS
17.6.2 EMERGING LEADERS
17.6.3 PERVASIVE PLAYERS
17.6.4 PARTICIPANTS
17.6.5 COMPANY FOOTPRINT: KEY PLAYERS
17.6.5.1 COMPANY FOOTPRINT
17.6.5.2 REGION FOOTPRINT
17.6.5.3 PLAYER TYPE FOOTPRINT
17.6.5.4 THERAPEUTIC AREA FOOTPRINT
17.6.5.5 END USER FOOTPRINT
17.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES
17.7.1 PROGRESSIVE COMPANIES
17.7.2 DYNAMIC COMPANIES
17.7.3 RESPONSIVE COMPANIES
17.7.4 STARTING BLOCKS
17.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
17.7.5.1 DETAILED LIST OF KEY STARTUPS/SMES
17.7.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
17.8 COMPANY VALUATION AND FINANCIAL METRICS
17.9 COMPETITIVE SCENARIOS
17.9.1 PRODUCT LAUNCHES & UPGRADES
17.9.2 DEALS
17.9.3 EXPANSIONS
17.9.4 OTHERS
18. COMPANY PROFILES
*IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, SERVICES, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE AI IN DRUG DISCOVERY MARKET LANDSCAPE*
18.1 KEY PLAYERS
18.1.1 NVIDIA CORPORATION
18.1.2 ALPHABET INC.
18.1.3 MICROSOFT CORPORATION
18.1.4 BENCHSCI
18.1.5 RECURSION PHARMACEUTICALS, INC.
18.1.6 SCHRODINGER, INC.
18.1.7 CERTARA, INC.
18.1.8 TEMPUS AI, INC.
18.1.9 ILLUMINA, INC.
18.1.10 INSILICO MEDICINE
18.1.11 XTALPI INC.
18.1.12 RELAY THERAPEUTICS
18.1.13 BENEVOLENTAI
18.1.14 NUMERION LABS
18.1.15 IKTOS
18.1.16 DEEP GENOMICS, INC.
18.1.17 VERGE GENOMICS
18.1.18 BPGBIO, INC.
18.1.19 INSITRO
18.1.20 GENERATE:BIOMEDICINES
19. RESEARCH METHODOLOGY
19.1 RESEARCH DATA
19.1.1 SECONDARY DATA
19.1.1.1 KEY DATA FROM SECONDARY SOURCES
19.1.2 PRIMARY DATA
19.1.2.1 KEY DATA FROM PRIMARY SOURCES
19.1.2.2 KEY PRIMARY PARTICIPANTS
19.1.2.3 BREAKDOWN OF PRIMARY INTERVIEWS (BY COMPANY TYPE, DESIGNATION, AND REGION)
19.1.2.4 KEY INDUSTRY INSIGHTS
19.2 MARKET SIZE ESTIMATION
19.2.1 BOTTOM-UP APPROACH
19.2.2 TOP-DOWN APPROACH
19.2.3 BASE NUMBER CALCULATION
19.3 MARKET FORECAST APPROACH
19.3.1 SUPPLY SIDE
19.3.2 DEMAND SIDE
19.4 DATA TRIANGULATION
19.5 FACTOR ANALYSIS
19.6 COMPANY EVALUATION MATRIX METHODOLOGY
19.7 RESEARCH ASSUMPTIONS
19.8 RESEARCH LIMITATIONS AND RISK ASSESSMENT
20. APPENDIX
20.1 KEY QUESTIONS ANSWERED BY THIS REPORT
20.2 DISCUSSION GUIDE
20.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.4 CUSTOMIZATION OPTIONS
20.5 RELATED REPORTS
20.6 AUTHOR DETAILS
世界の創薬分野におけるAI市場予測（～2031年） |
| 【英語タイトル】AI in Drug Discovery Market - Global Forecast to 2031 | |
 | ・商品コード：HIT 7445 ・発行会社（調査会社）：MarketsandMarkets ・発行日：2026年7月 ・ページ数：230 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後1営業日） ・調査対象地域：グローバル ・産業分野：医療・バイオ |
| Single User（1名様閲覧用） | USD4,950 ⇒換算￥772,200 | 見積依頼/購入/質問フォーム |
| Corporate License（法人閲覧用） | USD8,150 ⇒換算￥1,271,400 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 世界の創薬分野におけるAI市場は、2026年の50億9,000万米ドルから、2031年までに175億6,000万米ドルへと成長し、予測期間中の年平均成長率（CAGR）は28.1％になると見込まれています。2025年の市場規模は39億2,000万米ドルでした。この市場の成長を牽引しているのは、創薬の期間短縮と研究開発コストの削減を求める製薬業界の需要の高まり、生成AIや基盤モデルの導入拡大、マルチオミクスデータセットの利用可能性の拡大、そしてAIを活用した創薬プラットフォームへの投資である。製薬企業とAI技術プロバイダー間の戦略的提携の増加に加え、クラウドコンピューティング、ハイパフォーマンスコンピューティング、計算生物学の進歩が相まって、創薬の初期段階におけるAIの導入をさらに後押ししている。 創薬におけるAI市場は、仮説主導型研究からデータ駆動型創薬へと根本的な転換を遂げており、これにより研究者は、新規の生物学的ターゲットを特定し、分子間相互作用を予測し、有望な創薬候補をより高い確信を持って優先順位付けできるようになっています。AIにより、製薬企業はゲノミクス、プロテオミクス、トランスクリプトミクス、科学文献、実世界データにまたがる多様なデータセットを統合し、創薬パイプライン全体における意思決定を改善することが可能になっています。AIモデルの予測精度と拡張性が向上するにつれ、各組織は初期段階の創薬における中核的要素としてAIを導入し、ポートフォリオの質を高め、研究生産性を向上させ、治療薬開発の成功確率を高めている。 創薬分野におけるAI市場は、断片的で特定の段階に特化したアプリケーションから、統一されたワークフローの中で生物学的データ、計算化学、実験的検証を結びつける統合的な創薬エコシステムへと進化しています。製薬企業は、創薬パイプライン全体での意思決定を改善し、創薬候補の優先順位付けを迅速化し、より情報に基づいたポートフォリオ管理を実現するために、AIプラットフォームの採用を拡大しています。孤立したAIツールからエンタープライズ規模の創薬プラットフォームへのこの移行は、技術投資のあり方を変革し、AIを次世代の製薬イノベーションに向けた戦略的機能として位置づけています。 市場概要： 基準年（2025年）の市場規模：39億2,000万米ドル 現在の市場規模（2026年）：50億9,000万米ドル 予測市場規模（2031年）：175億6,000万米ドル CAGR（2026年～2031年）：28.1% セグメント別動向： 地域別リーダー：2025年、北米は創薬におけるAI市場の44.9％のシェアを占めた。 プロセス別リーダー：「ヒットからリードへの同定／リード創出」セグメントは、2026年から2031年にかけて最も高いCAGRを記録すると予想される。 ユースケース別リーダー：2026年から2031年にかけて、「デ・ノボ創薬」セグメントが最も高い成長率を示すと予測される。 治療領域別リーダー：2025年には、オンコロジー（がん治療）セグメントが38.6％という最大のシェアを占めた。 事業者タイプ別リーダー：2026年から2031年にかけて、「AI技術プロバイダー」セグメントが最も高い成長率を示すと予測される。 AIツール分野のリーダー：予測期間中、機械学習セグメントが市場を支配すると予想される。 導入モデル分野のリーダー：予測期間中、クラウドベースのモデルが28.7％のCAGRを示すと予測される。 エンドユーザー分野のリーダー：2025年、創薬におけるAI市場において、製薬・バイオテクノロジー企業セグメントが最大のシェアを占めた。 市場見通しと競争環境： NVIDIA Corporation、Schrodinger, Inc.、およびRecursionは、その高い市場シェアと製品展開の広さから、創薬分野におけるAI市場の主要プレイヤーとして挙げられた。 Xaira Therapeutics, Inc.、Converge Bio、CellType Inc.などは、専門的なニッチ分野で確固たる地位を築くことで、スタートアップや中小企業の中でも際立った存在となっており、新興の市場リーダーとしての潜在力を示している。 |
The global AI in drug discovery market is projected to grow from USD 5.09 billion in 2026 to USD 17.56 billion by 2031, at a CAGR of 28.1% during the forecast period. The market was valued at USD 3.92 billion in 2025. The market is driven by growing pharmaceutical demand to reduce drug discovery timelines and R&D costs, increasing adoption of generative AI and foundation models, expanding availability of multi-omics datasets, and investments in AI-enabled drug discovery platforms. Increasing strategic collaborations between pharmaceutical companies and AI technology providers, coupled with advances in cloud computing, high-performance computing, and computational biology, are further boosting the adoption of AI across early-stage drug discovery.
The AI in drug discovery market is undergoing a fundamental shift from hypothesis-driven research to data-driven drug discovery, enabling researchers to identify novel biological targets, predict molecular interactions, and prioritize high-potential drug candidates with greater confidence. AI is enabling pharmaceutical companies to integrate diverse datasets spanning genomics, proteomics, transcriptomics, scientific literature, and real-world evidence, improving decision-making throughout the discovery pipeline. As AI models become increasingly predictive and scalable, organizations are adopting AI as a core component of early-stage drug discovery to enhance portfolio quality, increase research productivity, and improve the probability of successful therapeutic development.
The AI in drug discovery market is evolving from fragmented, stage-specific applications toward integrated discovery ecosystems that connect biological data, computational chemistry, and experimental validation within a unified workflow. Pharmaceutical companies are increasingly adopting AI platforms to improve decision-making across the discovery pipeline, enabling faster prioritization of drug candidates and more informed portfolio management. This transition from isolated AI tools to enterprise-scale discovery platforms is reshaping technology investments and positioning AI as a strategic capability for next-generation pharmaceutical innovation.
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 3.92 Billion
Current Market Size (2026): USD 5.09 Billion
Forecast Market Size (2031): USD 17.56 Billion
CAGR (2026–2031): 28.1%
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for a 44.9% share of the AI in drug discovery market in 2025.
Process Leader: Hit-to-lead identification/lead generation segment is expected to register the highest CAGR between 2026 and 2031.
Use Case Leader: De novo drug design segment is projected to grow at the fastest rate from 2026 to 2031.
Therapeutic Area Leader: Oncology segment held the largest share of 38.6% in 2025.
Player Type Leader: AI technology providers segment is projected to grow at the fastest rate from 2026 to 2031.
AI Tool Leader: Machine learning segment is expected to dominate the market during the forecast period.
Deployment Model Leader: Cloud-based model is projected to exhibit a CAGR of 28.7% during the forecast period.
End User Leader: Pharmaceutical & biotechnology companies segment accounted for the largest share in the AI in drug discovery market in 2025.
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
NVIDIA Corporation, Schrodinger, Inc., and Recursion were identified as some of the star players in the AI in drug discovery market, given their strong market share and product footprint.
Xaira Therapeutics, Inc., Converge Bio, and CellType Inc., among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
MARKET ECOSYSTEM
The AI in Drug Discovery market operates within a collaborative ecosystem comprising pharmaceutical companies, biotechnology firms, AI technology providers, contract research organizations (CROs), academic and research institutions, cloud service providers, and regulatory agencies. Increasing convergence of artificial intelligence, computational biology, high-performance computing, and multi-omics research is accelerating innovation across the drug discovery value chain. Strategic collaborations between AI platform developers and pharmaceutical companies are enabling the development of scalable, data-driven discovery platforms, while advances in cloud computing and laboratory automation are supporting the transition toward integrated and AI-native drug discovery workflows.
Asia Pacific to be fastest-growing region in AI in drug discovery market
Asia Pacific is the fastest-growing AI in drug discovery market, supported by the rapid expansion of pharmaceutical and biotechnology research, increasing availability of genomic and clinical datasets, and growing investments in AI-native drug discovery companies. The region is emerging as a global hub for computational drug discovery, driven by expanding cloud infrastructure, high-performance computing capabilities, and a strong pipeline of AI-enabled biotechnology startups. China, Japan, South Korea, Singapore, and India are witnessing increasing adoption of AI across target identification, molecular design, and lead optimization, while collaborations between regional biotechnology companies and global pharmaceutical manufacturers continue to accelerate technology commercialization. These factors are positioning the region as a key growth engine for AI-enabled drug discovery during the forecast period.
AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX
NVIDIA Corporation (Star) holds a leading position in the AI in drug discovery market through its accelerated computing platforms, BioNeMo foundation models, and GPU-optimized AI ecosystem that power molecular simulation, predictive modeling, virtual screening, and generative drug design. Its strong collaborations with pharmaceutical companies, biotechnology firms, and research institutions, coupled with continued investments in high-performance computing and agentic AI, reinforce its leadership in enabling scalable AI-driven drug discovery. Microsoft Corporation (Emerging Leader) is rapidly strengthening its market presence through Azure AI, cloud-native infrastructure, and advanced AI development services that support large-scale biological data integration, AI model training, target identification, and collaborative drug discovery. The company’s expanding partnerships across the pharmaceutical and life sciences ecosystem position it as a key enabler of next-generation AI-powered therapeutics and digital R&D transformation.
| ★調査レポート[世界の創薬分野におけるAI市場予測（～2031年）] (コード：HIT 7445)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の創薬分野におけるAI市場予測（～2031年）]についてメールでお問い合わせ |
